Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Understanding resistance mechanisms to targeted therapies and immune checkpoint blockade in mutant KRAS lung cancers is critical to developing novel combination therapies and improving patient survival. Here, we show that MEK inhibition enhanced PD-L1 expression while PD-L1 blockade upregulated MAPK...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, David H., Rodriguez, B. Leticia, Diao, Lixia, Gaudreau, Pierre-Olivier, Padhye, Aparna, Konen, Jessica M., Ochieng, Joshua K., Class, Caleb A., Fradette, Jared J., Gibson, Laura, Chen, Limo, Wang, Jing, Byers, Lauren A., Gibbons, Don. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110980/
https://www.ncbi.nlm.nih.gov/pubmed/33972557
http://dx.doi.org/10.1038/s41467-021-22875-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110980/
https://www.ncbi.nlm.nih.gov/pubmed/33972557
http://dx.doi.org/10.1038/s41467-021-22875-w

Ejemplares similares